Oxford BioDynamics PLC PDMR Dealing / Grant of Share Options (3190S)

TIDMOBD

RNS Number : 3190S

Oxford BioDynamics PLC

08 July 2020

8 July 2020

Oxford BioDynamics Plc

( "OBD" or the "Company" and, together with its subsidiaries, the "Group")

PDMR Dealing / Grant of Share Options

Oxford BioDynamics Plc (AIM: OBD) (the "Company"), a biotechnology company focused on the discovery and development of epigenetic biomarkers, based on regulatory 3D genome architecture, using its liquid biopsy platform EpiSwitch(TM), announces that it has today granted 210,000 options over its ordinary shares of 1 pence each ("Ordinary Shares"), to Non-Executive Chairman, Dr Peter Pack. The options were granted under the Company's 2016 Non-Employee Share Option Plan with an exercise price of GBP1 per share.

One-third of the options granted will vest and become exercisable on the first anniversary of the grant date; one-third on the second anniversary and one-third on the third anniversary. Vested options will remain exercisable up to and including the tenth anniversary of the date of grant.

Following this grant, Peter Pack holds a total of 250,000 options over Ordinary Shares and is interested in 15,000 Ordinary Shares, representing 0.02% of the Company's current issued share capital.

The notification below, which is made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.

 
 1    Details of the person discharging managerial responsibilities/person 
       closely associated 
 a)   Name                        Peter Pack 
     --------------------------  --------------------------------------------- 
 2    Reason for the notification 
     ------------------------------------------------------------------------- 
 a)   Position/status             Director/PDMR 
     --------------------------  --------------------------------------------- 
 b)   Initial notification/       Initial notification 
       Amendment 
     --------------------------  --------------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------------- 
 a)   Name                        Oxford BioDynamics Plc 
     --------------------------  --------------------------------------------- 
 b)   LEI                         2138005Y1TK258O5U928 
     --------------------------  --------------------------------------------- 
 4    Details of the transaction(s): section to be repeated for (i) 
       each type of instrument; (ii) each type of transaction; (iii) 
       each date; and (iv) each place where transactions have been 
       conducted 
     ------------------------------------------------------------------------- 
 a)   Description of the          Ordinary Shares of 1 pence each 
       financial instrument,       ISIN: GB00BD5H8572 
       type of instrument 
       Identification code 
     --------------------------  --------------------------------------------- 
 b)   Nature of the transaction   Grant of share options 
     --------------------------  --------------------------------------------- 
 c)   Price(s) and volume(s)      210,000 ordinary shares at an exercise price 
                                   of 100 pence per share 
     --------------------------  --------------------------------------------- 
 d)   Aggregated information      N/A 
       - Aggregated volume 
       - Price 
     --------------------------  --------------------------------------------- 
 e)   Date of the transaction     8 July 2020 
     --------------------------  --------------------------------------------- 
 f)   Place of the transaction    Outside a trading venue 
     --------------------------  --------------------------------------------- 
 

For further details please contact:

 
 Oxford BioDynamics Plc 
  Jon Burrows, CEO 
  Paul Stockdale, CFO              [phone] 
 Shore Capital 
  Nominated Adviser and Broker 
  Stephane Auton 
  Edward Mansfield                [phone] 
 FTI Consulting 
  Financial Public Relations 
  Adviser 
  Natalie Garland-Collins         [phone] 
 

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry.

The Company's award-winning, proprietary technology platform, EpiSwitch(TM), aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.

In particular, EpiSwitch(TM) can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re--positioning programmes and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.

In April 2019, Oxford BioDynamics received the Queen's Award for Enterprise: Innovation. The Queen's Awards for Enterprise are the most prestigious awards for UK businesses.

Oxford BioDynamics is headquartered in the UK, and listed on the London Stock Exchange's AIM under the ticker "OBD". For more information please visit www.oxfordbiodynamics.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHKDLFBBDLBBBE

(END) Dow Jones Newswires

July 08, 2020 02:00 ET (06:00 GMT)